TORONTO, March 30, 2012 /PRNewswire/ — Great things come in small packages, or at least that’s what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for musculoskeletal pain, spasticity, fibromyalgia, and even cosmetics.

Developed by the Canadian-based innovator Intronix Technologies Corp. (http://www.intronixtech.com), the Myoguide™ system detects critical information about the tissues targeted for injection. It then provides instant reporting that increases the odds for successful, accurately measured injections, thus helping minimize mistakes, inaccurate dosages and potential side effects.

“With TUV and CE Mark Certifications, the Myoguide system has already been in clinical use both in Europe and Canada,” says Dr. Evan Friedman, president of Intronix Technologies. “But we’ve just now received our long-awaited clearance to market from the FDA, and I couldn’t be more excited. It’s thrilling to officially launch this technology in the U.S. because it’s a highly significant, very needed tool for ensuring best practices within our industry. With Myoguide, administering injections is now safer, more efficient and more effective than ever.”

Small and portable, the handheld package can be easily transported, plus it’s easy to use. Key features include the ability to see and hear EMG signals, display real-time analyzed EMG, and determine stimulation-location capability. This provides both the quantitative and qualitative feedback necessary for clinicians to make decisions about treatment, specifically injecting neuromodulators such as Botox and Dysport for the management of pain, movement disorders, spastic muscle management and cosmetic applications. Myoguide incorporates patent-pending technology that’s backed by a 24-month guarantee, and ongoing service and support.

With its recent FDA clearance, Intronix Technologies is now actively promoting the system to the U.S. marketplace through its new e-commerce website: http://www.intronixtech.com. In addition, the company will showcase the system at the 64th American Academy of Neurology’s Annual Meeting, taking place April 21-28, 2012 in New Orleans (http://www.aan.com/go/am12), Booth 631.

“Myoguide is a ‘dream come true’ technology for doctors, researchers and clinicians,” Friedman says. “Anyone using it will have a competitive advantage in delivering procedures with newfound precision and safety, yet it’s really a must-have tool for any professional who administers these very specific types of injections.”

About Intronix Technologies Corporation

Located just outside Toronto, Ontario, Intronix Technologies Corporation designs and produces progressive electromyographic (EMG) systems for applications in the diagnosis and management of myofascial pain, spasticity, and fibromyalgia. Its innovations in injection guidance provide technology that drives clinical solutions to deliver confidence, improve workflow efficiency, and provide a better patient experience. Intronix Technologies is known for its exceptional equipment, plus its comprehensive customer-support programs that are developed to maximize the lifecycle value of equipment through responsive service maintenance and significant software support.

Contact:

Dr. Evan Friedman
President, Intronix Technologies Corporation
800-819-9996
drevan@intronixtech.com

This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Intronix Technologies Corporation